The Asia Pacific Large Molecule Drug Substance CDMO Market would witness market growth of 9.1% CAGR during the forecast period (2022-2028).
The demand for biologics and generic drugs is increasing exponentially, which has also propelled high competition in the pharmaceutical industry. The benefit of increased competition resulted in increased the pace of technological innovations increased. The downside to this was rising cost constraints.
As a result, the pharmaceutical industry’s dependence on CDMOs has increased to aid in overcoming many limitations. Through CDMOs, the pharmaceutical industry can progress its clinical candidate development, candidate registration, market authorization, and manufacturing. Many companies in the industry have also revisited their troublesome production operations to manage company assets and resources effectively.
This has helped the companies to regulate their finances. Additionally, CDMOs are able to provide cost-effective manufacturing and development services. Therefore, outsourcing development and manufacturing processes to a CDMO helps pharmaceutical companies increase their technical abilities without the restriction of rethinking equipment prices.
In this region, CDMOs providing services for the processing and development of biologics is growing. This growth is primarily influenced by the region’s massive and growing elderly proportion, who are demanding for better performing medicines. Additionally, in comparison to western regions, the affordability of biopharmaceuticals is high the Asia Pacific region. The emergence of biosimilars, which are low-cost generic variants of biologics, are driving up the investments for the regional CDMOs.
The China market dominated the Asia Pacific Large Molecule Drug Substance CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,965.8 million by 2028. The Japan market is estimated to grow a CAGR of 8.5% during (2022 - 2028). Additionally, The India market would experience a CAGR of 9.8% during (2022 - 2028).
Based on Application, the market is segmented into Mammalian, Microbial and Others. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Contract Manufacturing Type, the market is segmented into Commercial and Clinical. Based on Contract Development Type, the market is segmented into Cell Line Development and Process Development. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Large Molecule Drug Substance CDMO Market is Projected to reach USD 19.2 Billion by 2028, at a CAGR of 8.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG.
By Application
By Service
By End-user
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
